Process Worker ~ Compounding Assistant

Baxter's shares fall as Q3 probability dips despite revenue growth. Baxter's shares fell by over 4% on 29 October after adjusted earnings per share (EPS) dipped 16% year-over-year, despite positive revenue results. Baxter has reported Q3 revenues of almost $3bn, but as it raises its 2026 outlook for the second consecutive quarter amid the positive financial performance, the company's stock price also took a hit. On an adjusted basis, net income in Q3 was $0.58 per diluted share, decreasing 16% compared to the same period last year. This was partly because of a higher effective tax rate. Still, revenue of almost $3bn was indicative of a 5% year-over-year (YoY) rise. As a result, Baxter now expects its 2026 earnings to land in the $2.05 to $2.15 per diluted share range, up from $1.95 to $2.15 previously. Baxter's shifting fortunes in recent quarters follow a series of setbacks it experienced throughout Q2 and Q3 2025, leading it to take actions including the establishment of its growth and performance system (GPS) in October 2025, to tighten up its internal protocols and address recent issues with products including its Novum infusion pump. Throughout its recent more positive quarters, Baxter has made much ado about turning its operations, having been hamstrung by a slew of infusion pump recalls throughout recent years that caused its Q2 2025 revenues to come in below analysts' estimates at $2.81bn. However, it appears that quality control issues continue to blight Baxter and may have influenced market sentiment despite its positive Q3 performance. Baxter received a warning letter from the US Food and Drug Administration (FDA) on 29 September that struck a familiar tone, again citing that multiple current good manufacturing practice (CGMP) violations had been uncovered at one of the company's US drug manufacturing sites. These issues and the adjusted EPS dip struck a cautious note with investors. Releasing its Q3 financials ahead of market open on 29 October, Baxter's shares, listed on the New York Stock Exchange (NYSE), saw a slight uptick to $26 at market open, before declining by over 4% to a $24.61 close. Baxter has a market cap of $12.15bn. Meanwhile, a Jefferies research note agreed with Baxter's assessment that execution was improving. It noted, however, that it foresees a "challenging '27 ahead", due to factors including ongoing inflationary pressures and Baxter's plans to fully exit its transition services agreements (TSA) in relation to the $3.5bn sale of its kidney care unit to investment firm Carlyle in August 2024. Once Baxter exits the TSA in January 2027, it will no longer receive fees from Carlyle. This is customary under a typical TSA through which the buyer gradually assumes responsibility for the business and no longer relies on seller support. More than two-thirds of Baxter's Q3 revenues stemmed from its medical products & therapies segment, which totalled around $2.1bn, reflecting a 6% YoY uptick. According to the Illinois-based company, the segment's performance was primarily driven by its infusion therapies and platforms division, chiefly due to sales in relation to infusion systems and drug compounding and IV solutions, with advanced surgery products also contributing to the segment's overall performance. Baxter's healthcare systems and technologies segment, meanwhile, drew in revenues of around $806m, indicative of a 4% uptick YoY. Performance in the quarter reflected strong demand for care and connectivity solutions products, driven by growth in global surgical solutions and patient support systems, with the results also reflecting growth in front line care, Baxter stated. Andrew Hider, Baxter's president and CEO, commented: "We delivered a strong third quarter, with growth across all segments and divisions globally." "We continue to make steady progress stabilising the business, strengthening the balance sheet and driving continuous improvement. Our results reinforce our confidence in this direction as we build a stronger foundation for sustainable growth and long-term value creation." Give your business an edge with its leading industry insights.

Qatar among the first to adopt baxter's secure, connected vital signs monitoring technology. New patient monitoring solution automates vital signs documentation and protects patient data, supporting Qatar's National Vision 2030 ambitions for an integrated health system Published on October 25, 2026 | 11:57 AM Baxter International Inc. (NYSE:BAX), a leader in patient monitoring, physical assessment and vision screening products, announced the launch of the Welch Allyn Connex 360 Vital Signs Monitor in Qatar, among the first markets to introduce the technology. The launch event in Doha, brought together healthcare leaders, clinicians, and IT specialists from the Ministry of Interior, Hamad Medical Corporation, The View Hospital, Military Medical City Hospital, and Sidra Medicine, who experienced live demonstrations of Connex 360's automated documentation and Early Warning Score capabilities. The launch comes as Qatar continues to advance its healthcare transformation agenda under Qatar National Vision 2030 and the National Health Strategy 2024-2030 "Health for All," which aims to build a health-focused society supported by an integrated health system centered on clinical excellence, sustainability and innovation. Continued investment in digital health infrastructure and interoperable systems has created an environment where connected care technologies can be adopted and scaled effectively. Vital signs are among the most frequently recorded measurements in healthcare settings, yet in many environments they continue to be documented manually. This process can take valuable time away from patient care and may introduce transcription errors where accuracy is critical. As the latest innovation, Connex 360 captures a complete set of vital signs, including blood pressure, temperature, pulse rate, and blood oxygen levels, in less than a minute. Configurable Early Warning Score protocols help care teams identify patients whose condition may be deteriorating, supporting earlier clinical intervention. The monitor automatically records patients' vital signs and transfers them securely to hospital information systems, reducing the need for manual documentation. "Healthcare systems across Qatar continue to embrace innovation that improves the quality and efficiency of care," said Beata Karasinska, general manager, Central Eastern Europe, Middle East, Türkiye and Africa (CEEMEA) at Baxter. "We are proud to introduce Connex 360 in Qatar and to support healthcare providers with a connected monitoring solution that helps clinicians access timely patient information, streamline workflows and spend more time with their patients, with the confidence that patient data is protected. This launch reflects our long-term commitment to the country and to our mission to Save and Sustain Lives." As healthcare systems become increasingly connected, protecting patient information remains a priority. Connex 360 uses end-to-end encryption and certificate-based authentication to help safeguard data as it moves between the bedside and hospital systems. Building on a long history of innovation in patient monitoring through the Welch Allyn portfolio, Baxter continues to invest in connected care technologies that help healthcare providers improve efficiency, enhance patient safety and support better clinical outcomes. Last Edited October 25, 2026 | 12:02 PM